Q1 2027 Haemonetics Corp Earnings Call Transcript

Aug 6, 2026 / 12:00 PM GMT

Release Date Price: €70 (-2.78%)

Transcript 10-Q8-K

Key Points

Positve

Haemonetics Corp (HAE) delivered a strong first quarter with revenue of $339 million, up 6% reported and organic, and raised its full-year fiscal 2027 revenue and earnings guidance.
The company's MedSurg segment returned to growth, with vascular closure growing in the low double-digits, driven by the VASCADE MVP XL expanded indication and strong commercial execution.
Plasma revenue grew 8% organically, supported by double-digit disposable growth, share gains, and the successful rollout of Persona Plus, which is delivering yield improvements exceeding 5% for early adopters.
The company generated exceptional cash flow, with operating cash flow of $52 million (three times the prior year) and free cash flow conversion of 75% in Q1, a seasonally weak quarter, and 106% on a trailing twelve-month basis.
Haemonetics Corp (HAE) is seeing strong momentum in hemostasis management, with mid-teens disposable growth and a durable growth runway, supported by the global rollout of the heparinase neutralization cartridge.
The company successfully outran the overhang from the CSL divestiture and customer loss, with current results now reflecting clean, recurring growth going forward.

Negative

Adjusted operating margin declined 70 basis points year-over-year to 23.4%, impacted by a difficult prior-year software comparison and external cost pressures, including higher personnel and freight expenses.
The Interventional Technologies segment only grew 3% organically, with softness in peripheral and coronary procedures, esophageal cooling, and a decline in the OEM business partially offsetting strong vascular closure growth.
Cell-salvage capital upgrades slowed, contributing to a deceleration in the Blood Management Technologies growth within MedSurg.
The company faces sustained external cost pressures, including higher oil prices, transportation costs, and material inflation, which are expected to offset a $7 million tariff refund in Q2.
Other apheresis revenue declined 3% organically due to portfolio optimization and order timing, and the company remains conservative in its guidance, not including potential upside from higher collection volumes or accelerated Persona Plus adoption.
Adjusted earnings per diluted share growth of 4% was tempered by higher interest expense, unfavorable foreign exchange, and a higher tax rate, despite strong underlying operating performance.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HAE.N - Haemonetics Corp
Q1 2027 Haemonetics Corp Earnings Call
Aug 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Humanetics Corporation First Quarter 2027 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today. Olga Gayant, Vice President, Investor Relations and Treasurer, please go ahead.

-------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.